Caribbean Island Urinary Iodine Survey 2018

Overview

Many of the Caribbean island nations have no data on iodine status in their populations. Iodine deficiency in children can reduce IQ but can be easily corrected through a program of salt iodization. The study will be located at 11 islands of the Caribbean region. At each of the 11 study sites, we will measure the iodine status in school-age children by collecting morning spot urine samples for measurement of urinary iodine concentration (UIC). We will also measure height and weight in all children. We will collect a repeat, next-day spot urine sample in 1/3rd of children to adjust for intra-individual variation in spot UIC and calculate the distribution of population intake.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 31, 2018

Detailed Description

In well-controlled randomized trials in Europe and New Zealand, even mild-to-moderate iodine deficiency in school-age children reduces IQ (1); thus, its critical to avoid iodine deficiency in this age group. In countries effected by iodine deficiency, its sustainable elimination through iodized salt can contribute to socioeconomic development. The goal to eliminate iodine deficiency was first adopted globally at the World Summit for Children in 1990, and in 1994, WHO and UNICEF concluded that salt iodization is a safe, cost-effective and sustainable strategy to control iodine deficiency (2). In 2005, the World Health Assembly called on national governments to report on their iodine nutrition every three years. However, before the present survey, the ten countries included in this project had no data on iodine status in their populations, and household access to adequately iodized salt was also unknown. Thus, the study objectives were: – Assess the distribution of iodine intake of school-age children and their iodine status by measuring urinary iodine concentrations; – Assess the iodine content of household salt and of seasoning powders; – Based on the above, provide the preliminary evidence base on which to make initial recommendations for iodine strategy/programs in the region.

Arms, Groups and Cohorts

  • Jamaica
    • School aged children 6 – 12 years living in Jamaica
  • Trinidad and Tobago
    • School aged children 6 – 12 years living in Trinidad and Tobago
  • Belize
    • School aged children 6 – 12 years living in Belize
  • Barbados
    • School aged children 6 – 12 years living in Barbados
  • St. Lucia
    • School aged children 6 – 12 years living in St. Lucia
  • Grenada
    • School aged children 6 – 12 years living in Grenada
  • St. Vincent & the Grenadines
    • School aged children 6 – 12 years living in St. Vincent & the Grenadines
  • Antigua
    • School aged children 6 – 12 years living in Antigua
  • Dominica
    • School aged children 6 – 12 years living in Dominica
  • St. Kitts and Nevis
    • School aged children 6 – 12 years living in St. Kitts and Nevis

Clinical Trial Outcome Measures

Primary Measures

  • Iodine status (UIC in spot urine samples)
    • Time Frame: March 2018 to May 2019
    • Assessment of iodine status based on median urinary iodine concentration in spot urine samples

Secondary Measures

  • Iodine content in salt
    • Time Frame: January 2019 to May 2019
    • Measurement of iodine concentration in salt samples brought in by participants

Participating in This Clinical Trial

Inclusion Criteria

1. age at study enrolment 6 to 12 years 2. healthy; no known history of major medical illnesses and taking no chronic medications; 3. residence at the respective study site for 12 months or longer; 4. no use of iodine containing dietary supplements during the last 6 months; 5. no use of X-ray / CT contrast agent or iodine containing medication within the last year.

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: 12 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Swiss Federal Institute of Technology
  • Collaborator
    • Pan American Health Organization
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael B Zimmermann, Dr. Prof., Principal Investigator, ETH Zurich, Iodine Global Network

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.